Brokerages Set Omnicell, Inc. (NASDAQ:OMCL) Target Price at $42.20

Omnicell, Inc. (NASDAQ:OMCL - Get Free Report) has received an average rating of "Hold" from the six brokerages that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $42.20.

Several research analysts have recently issued reports on OMCL shares. Wells Fargo & Company reduced their price target on Omnicell from $28.00 to $26.00 and set an "equal weight" rating on the stock in a research report on Friday, February 9th. Benchmark cut their target price on Omnicell from $42.00 to $38.00 and set a "buy" rating for the company in a research note on Friday, February 9th. Finally, Barclays started coverage on shares of Omnicell in a research report on Wednesday, January 3rd. They set an "underweight" rating and a $33.00 price target on the stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Versant Capital Management Inc raised its position in shares of Omnicell by 561.4% during the 3rd quarter. Versant Capital Management Inc now owns 549 shares of the company's stock valued at $25,000 after purchasing an additional 466 shares during the period. Belpointe Asset Management LLC grew its stake in shares of Omnicell by 92.2% in the 1st quarter. Belpointe Asset Management LLC now owns 494 shares of the company's stock worth $29,000 after buying an additional 237 shares in the last quarter. KBC Group NV purchased a new position in shares of Omnicell in the 4th quarter worth $38,000. Penserra Capital Management LLC grew its stake in shares of Omnicell by 180.8% in the 2nd quarter. Penserra Capital Management LLC now owns 629 shares of the company's stock worth $46,000 after buying an additional 405 shares in the last quarter. Finally, Covestor Ltd boosted its stake in shares of Omnicell by 65.6% during the 3rd quarter. Covestor Ltd now owns 1,355 shares of the company's stock worth $61,000 after purchasing an additional 537 shares during the period. 97.70% of the stock is currently owned by institutional investors.

Omnicell Trading Down 0.0 %

Shares of Omnicell stock traded down $0.01 on Friday, reaching $29.23. 447,440 shares of the company were exchanged, compared to its average volume of 562,563. The stock has a fifty day moving average price of $29.23 and a 200-day moving average price of $35.27. The firm has a market capitalization of $1.34 billion, a price-to-earnings ratio of -64.96 and a beta of 0.74. The company has a current ratio of 2.52, a quick ratio of 2.22 and a debt-to-equity ratio of 0.48. Omnicell has a fifty-two week low of $25.69 and a fifty-two week high of $77.14.

Omnicell (NASDAQ:OMCL - Get Free Report) last issued its earnings results on Thursday, February 8th. The company reported $0.12 earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.22. The company had revenue of $258.85 million for the quarter, compared to analyst estimates of $256.00 million. Omnicell had a positive return on equity of 3.43% and a negative net margin of 1.78%. On average, analysts expect that Omnicell will post 0.1 EPS for the current year.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.